Sugi Predict

Sugi Predict / Compounds / SCHEMBL379807

SCHEMBL379807

SCHEMBL379807

NC(=O)c1cc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.76
▸ KDM4E B2RXH2 1/20 0.76
▸ SMN1; SMN2 Q16637 1/20 0.76
▸ PDE10A Q9Y233 1/20 0.76
▸ DHODH Q02127 4/20 0.71
▸ RXFP1 Q9HBX9 1/20 0.71
▸ CYP3A4 P08684 1/20 0.64
▸ POLB P06746 1/20 0.63
▸ NCOA1 Q15788 1/20 0.61
▸ NCOA3 Q9Y6Q9 1/20 0.61
▸ TACR3 P29371 3/20 0.61
▸ TSHR P16473 1/20 0.61
▸ AKR1C3 P42330 1/20 0.60
▸ AKR1C2 P52895 1/20 0.60
▸ AKR1C1 Q04828 1/20 0.60
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ GFER P55789 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29586433 1.00 LMNA (0.76) LMNAKDM4ESMN1; SMN2PDE10ADHODH
SCHEMBL20414373 0.90 DHODH (0.62) LMNAKDM4ESMN1; SMN2PDE10ADHODH
SCHEMBL30604089 0.88 KMT2A (0.73) LMNAKDM4ESMN1; SMN2PDE10ADHODH
SCHEMBL17308320 0.88 KMT2A (0.73) LMNAKDM4ESMN1; SMN2PDE10ADHODH
SCHEMBL7479593 0.87 DHODH (0.81) LMNAKDM4ESMN1; SMN2PDE10ADHODH
Cinchophen SCHEMBL7588217 0.86 KDM4E (1.00) LMNAKDM4ESMN1; SMN2PDE10ADHODH
Cinchophen SCHEMBL29376617 0.86 KDM4E (1.00) LMNAKDM4ESMN1; SMN2PDE10ADHODH
Cinchophen SCHEMBL25519 0.86 KDM4E (1.00) LMNAKDM4ESMN1; SMN2PDE10ADHODH
Cinchophen SCHEMBL10757475 0.85 KDM4E (0.97) LMNAKDM4ESMN1; SMN2PDE10ADHODH
Cinchophen SCHEMBL4464779 0.85 KDM4E (0.97) LMNAKDM4ESMN1; SMN2PDE10ADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224147-A1 METHODS AND COMPOSITIONS Relevare Aust. Pyt. Ltd. (AU) 2011-09-15 — — US claimed
US-20100316678-A1 COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN CNSBIO PTY LTD. (AU) 2010-12-16 — — US claimed
EP-2175886-A1 COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN CNSBio Pty Ltd (AU) 2010-04-21 — — EP claimed
WO-2010012043-A1 METHODS AND COMPOSITIONS CNSBIO PTY LTD (AU) 2010-02-04 — — WO claimed
WO-2009000038-A1 COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN CNSBIO PTY LTD (AU) 2008-12-31 — — WO claimed
EP-1289560-A1 NOVEL SOLID DISPERSION COMPOSITIONS SmithKline Beecham Corporation (US) 2003-03-12 — — EP claimed
WO-2001095939-A1 NOVEL SOLID DISPERSION COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-20 — — WO claimed
CN-110105279-B Quinoline STAT3 specific inhibitor and preparation method and application thereof 中山大学 2022-09-16 — — CN disclosed
WO-2020243496-A1 A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2020-12-03 — — WO disclosed
US-10633369-B2 Method of inhibiting DYRK1B 4 SC AG (DE) 2020-04-28 — — US disclosed
US-10179770-B2 Quinolines derivatives as novel anticancer agents GENOSCIENCE PHARMA (FR) 2019-01-15 — — US disclosed
US-10179770-B2 Quinolines derivatives as novel anticancer agents GENOSCIENCE PHARMA (FR) 2019-01-15 — — US disclosed
CN-105102442-B Quinoline as anticarcinogen 基因科学医药公司 2018-11-09 — — CN disclosed
WO-2006050991-A1 COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE SMITHKLINE BEECHAM CORPORATION (US) 2006-05-18 — — WO disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 — — US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 — — WO disclosed
CN-1353609-A Amide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO (US) 2002-06-12 — — CN disclosed
EP-0983243-A1 NOVEL QUINOLINE- AND NAPHTHALENECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF INHIBITING CALPAIN SMITHKLINE BEECHAM CORPORATION (US) 2000-03-08 — — EP disclosed
CN-1207730-A Quinoline derivs. SMITHKLINE BEECHAM SPA (IT) 1999-02-10 — — CN disclosed
WO-1998041506-A1 NOVEL QUINOLINE- AND NAPHTHALENECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF INHIBITING CALPAIN SMITHKLINE BEECHAM CORPORATION (US) 1998-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10179770-B2 Quinolines derivatives as novel anticancer agents NQO2, MKI67, NQO1 LMNA 2412/4885KDM4E 979/4885SMN1; SMN2 3931/4885
US-10633369-B2 Method of inhibiting DYRK1B SMO, GLI1, GRK2 LMNA 4587/4885KDM4E 996/4885SMN1; SMN2 4360/4885
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 LMNA 3391/4885KDM4E 1190/4885SMN1; SMN2 1477/4885
US-20110224147-A1 METHODS AND COMPOSITIONS OPRK1, OPRL1, OPRM1 LMNA 4664/4885KDM4E 1986/4885SMN1; SMN2 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.